Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts says
April 17, 2020 at 07:08 AM EDT
Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS.
